Plozasiran (REDEMPLO), an siRNA therapy targeting familial chylomicronemia syndrome, achieved FDA approval in November 2025 and has accumulated 180 patient users within its first months, with long-term data demonstrating 83% median triglyceride reduction and no acute pancreatitis events over two years. This represents a mechanistic advance in lipid metabolism intervention for a severe genetic disorder with limited treatment options.
Key Points
- 83% median triglyceride reduction sustained over two years of treatment
- 180 patients dosed within months; zero adjudicated acute pancreatitis events
- siRNA mechanism targets APOC3 pathway, distinct from competing inhibitor classes
Longevity Analysis
Familial chylomicronemia syndrome carries substantial cardiovascular and metabolic risk through extreme triglyceridemia and recurrent pancreatitis. Plozasiran's mechanism—silencing apolipoprotein C-III expression through RNA interference—addresses the disorder at the genetic level rather than compensating downstream. The absence of pancreatitis events across two years, paired with sustained triglyceride reduction, eliminates a primary source of acute metabolic decompensation. For patients with this genetic lipid disorder, this approach removes a significant barrier to metabolic stability and extends the therapeutic window for preventing cumulative organ damage.
Original published by LT Wire.